Peptide
Sermorelin
SaveA synthetic 29-amino-acid fragment of growth-hormone-releasing hormone (GHRH 1-29). Previously FDA-approved for pediatric growth hormone deficiency, now used off-label in anti-aging medicine.
Quick verdict
The original GHRH analog with the longest track record. FDA approval was withdrawn for commercial reasons, not safety. Widely used in anti-aging clinics.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Was FDA-approved as Geref for GH deficiency testing. Clinical data support GH/IGF-1 increase and body-composition improvements. Manufacturing difficulties led to market withdrawal.
Benefits
- Longest clinical track record among GHRH analogs
- Preserves physiologic pulsatile GH release
- Documented improvements in body composition and sleep quality
Dosage notes
Typical anti-aging clinic dose: 200–500 mcg subcutaneously at bedtime.
Side effects
- Injection-site reactions
- Facial flushing
- Headache
- Dizziness
- Mild water retention
Who should be cautious
No longer FDA-approved (market withdrawal, not safety recall). Long-term safety of chronic use is not fully established.
What this page cannot tell you
Solid pharmacological data but clinical outcome studies for anti-aging are limited. Market withdrawal was business-related.
Leaderboard scores
- Muscle38
- Recovery35
- Sleep30
- Longevity25
Write a review
Sign in to write a review.